Xie Yang

Xie Yang, listed as chief executive, has filed trades across 2 companies (mainly through HKEX), most often in Futian Holdings Ltd. and Zylox-Tonbridge Medical Technology Co., Ltd. In total, 8 filings cover trades dated from 29 June 2022 to 29 April 2026.

In open-market terms, that means 1 purchase on one side and 4 sales worth €2.4M on the other. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show no purchases and 1 sale.

The latest filing, published on 30 April 2026, reports a transaction of €1.1M in Zylox-Tonbridge Medical Technology Co., Ltd. The last purchase on record was published on 1 July 2022, which is 1,591 days ago. The median gap between a trade and its publication by HKEX is 1 day. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from HKEX disclosures alone and does not predict where the share price will go.